Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919119449Aexternal-prioritypatent/GB9119449D0/en
Priority claimed from GB919119692Aexternal-prioritypatent/GB9119692D0/en
Priority claimed from GB919122473Aexternal-prioritypatent/GB9122473D0/en
Priority claimed from GB919122474Aexternal-prioritypatent/GB9122474D0/en
Priority claimed from GB919122624Aexternal-prioritypatent/GB9122624D0/en
Application filed by Smithkline Beecham PlcfiledCriticalSmithkline Beecham Plc
Publication of MX9205204ApublicationCriticalpatent/MX9205204A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se proporciona un compuesto de la fórmula (I) o una sal del mismo farmacéuticamente aceptable: en la que las variables están definidas en la especificación, para utilizarse en la fabricación de un medicamento que se utiliza en el tratamiento de desórdenes gastrointestinales, desórdenes cardiovasculares y desórdenes del SNC.A compound of formula (I) or a pharmaceutically acceptable salt thereof is provided: wherein the variables are defined in the specification, for use in the manufacture of a medicament for use in the treatment of gastrointestinal disorders, cardiovascular disorders and CNS disorders.
MX9205204A1991-09-121992-09-11
PHARMACEUTICAL COMPOSITION COMPRISING ANTAGONIST COMPOUNDS OF THE 5-HYDROXITRIPTAMINE RECEPTOR
MX9205204A
(en)
Non-peptidyl integrin inhibitors specific for the GPIIbIIIa receptor, pharmaceutical compositions comprising such a compound, and the use of the compounds in the manufacture of medicaments
DERIVATIVES OF IMIDAZO PIRIDINA SUBSTITUTED FOR THE INHIBITION OF THE GASTRIC ACID SECRETION; A SALT OF THE SAME, PROCEDURE FOR ITS PREPARATION, PHARMACEUTICAL FORMULATION THAT CONTAINS THEM AND THE USE OF SUCH COMPOUND FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
Medicament containing a pharmaceutically acceptable carrier and the compound of the structure (7-alpha, 17-alpha) -17-hydroxy-7-methyl-19-nor-17-pregn-5 (10) -ene-20-yne-3 -one contains.